Investors in TG Therapeutics, Inc. TGTX need to pay close attention to the stock based on moves in the options market lately. That is because the Aug 15, 2026 $15.00 Call had some of the highest ...
With earnings season in full swing, biotechnology stocks were volatile today. If approved, avacincaptad pegol would be the first commercial rival to Apellis' FDA-approved GA medicine, Syfovre. Apellis ...
In trading on Monday, shares of TG Therapeutics Inc (Symbol: TGTX) crossed above their 200 day moving average of $34.34, changing hands as high as $35.07 per share. TG Therapeutics Inc shares are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback